ARHGEF39 Activators
ARHGEF39 Activators comprise chemicals targeting multiple pathways that indirectly influence ARHGEF39 function. For example, LPA and S1P are ligands for respective G-protein coupled receptors, both initiating cascades that ultimately activate Rho GTPases, which are the direct targets of ARHGEF39's guanyl-nucleotide exchange function. The role of ARHGEF39 in facilitating this exchange function can therefore be elevated in the presence of these ligands. Similarly, compounds like Forskolin, which increase cAMP levels, and Calpeptin, a calpain inhibitor, also demonstrate the ability to modulate ARHGEF39's activity by influencing Rho GTPase levels or activity.
On the other hand, compounds like U0126 and PD98059 are MEK inhibitors that attenuate the MAPK pathway. This action can elevate Rho GTPase activity, thus leading to increased ARHGEF39 activity. Other inhibitors like Y-27632 and H1152 focus on inhibiting ROCK, a downstream effector of Rho GTPases. By inhibiting ROCK, these compounds encourage the cycling of Rho GTPases between their active and inactive states, indirectly contributing to ARHGEF39 activation. This provides a comprehensive landscape of chemicals capable of activating ARHGEF39 by targeting related pathways or cellular processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lysophosphatidic Acid | 325465-93-8 | sc-201053 sc-201053A | 5 mg 25 mg | $98.00 $341.00 | 50 | |
Directly interacts with LPA receptors, stimulating downstream Rho GTPase activation. This can lead to activation of ARHGEF39 by enhancing its guanyl-nucleotide exchange activity, thereby aiding in positive regulation of cell migration. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Binds to S1P receptors, which can activate Rho GTPase. ARHGEF39, facilitating the guanyl-nucleotide exchange on Rho GTPases, becomes activated in this context. | ||||||
Phorbol-12,13-dibutyrate | 37558-16-0 | sc-202285 | 1 mg | $124.00 | 3 | |
Activates Protein Kinase C (PKC), which can phosphorylate and activate ARHGEF39, promoting its guanyl-nucleotide exchange activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
ROCK inhibitor that enhances Rho GTPase cycling, indirectly contributing to ARHGEF39 activation. | ||||||
Calpeptin | 117591-20-5 | sc-202516 sc-202516A | 10 mg 50 mg | $121.00 $456.00 | 28 | |
Calpain inhibitor that can result in the upregulation of Rho GTPases and, by extension, ARHGEF39 activity. | ||||||
Neomycin sulfate | 1405-10-3 | sc-3573 sc-3573A | 1 g 5 g | $27.00 $35.00 | 20 | |
Phosphatidylinositol phosphatase inhibitor, increasing PIP2 levels. This could favor ARHGEF39's interaction with Rho GTPases, enhancing its activity. | ||||||
H-1152 dihydrochloride | 451462-58-1 | sc-203592 sc-203592A | 1 mg 5 mg | $104.00 $364.00 | 7 | |
ROCK inhibitor that, like Y-27632, enhances Rho GTPase cycling and thereby can activate ARHGEF39. | ||||||
Suramin sodium | 129-46-4 | sc-507209 sc-507209F sc-507209A sc-507209B sc-507209C sc-507209D sc-507209E | 50 mg 100 mg 250 mg 1 g 10 g 25 g 50 g | $152.00 $214.00 $728.00 $2601.00 $10965.00 $21838.00 $41096.00 | 5 | |
Non-selective P2 purinergic antagonist. By blocking P2 receptors, this compound could alter intracellular calcium levels, affecting Rho GTPase activity and thus ARHGEF39's guanyl-nucleotide exchange function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
Another MEK inhibitor affecting the MAPK pathway. By attenuating the MAPK pathway, it may result in increased activity of ARHGEF39 through elevated Rho GTPase activity. | ||||||